Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by stockarchangelon Sep 07, 2016 7:37pm

160 Views

Post# 25215859

RE:RE:RE:RE:RE:RE:New Sirona twitter post

How about this: 10% of skin whitener market = $2 billion x 15% royalty = $300 million / 200 million shares =$1.50 p/s revenue. Assuming tremendous expansion of labs and projects leaving only $1 p/s in net x 20 PE = $20 p/s. Not all that much of a stetch. But.......we need to sign that licensing agreement first.

Bullboard Posts

Options trading in a volatile macro environment